by Sven Parplies, Euro on Sunday
The future is traded on the stock exchange, not the present. This is particularly evident at Moderna. The biotech firm, which was still in the red in 2020, is likely to generate more than $ 11 billion in net profit this year thanks to its successful corona vaccine. However, the enthusiasm for the share has evaporated. The problem from the stock exchange’s point of view: Moderna has so far not been able to show a clear perspective for the time after the pandemic.
First results in the development of a flu vaccine did not deliver the results hoped for and dampened confidence that Moderna could replicate the success of its corona vaccine in the fight against other diseases thanks to mRNA technology. When it comes to flu vaccinations, Moderna has to compete against established products. Analysts are currently assuming that Moderna’s profit will halve by 2024. Thanks to its technology and financial resources, the group remains an investment with clear opportunities, but also corresponding risks. Newcomers should wait until the course has stabilized. Stop position.
Branch: biotechnology
Headquarters: Cambridge, Massachusetts (USA)
Market value: 94.4 billion ??
Editor’s note: Every week investors can vote on the main page of finanzen.net which shares should be discussed. The voting runs until Wednesday. Take part! Please scroll far down (right side)!
_________________________________
More news about Moderna Inc
Image Sources: Ascannio / Shutterstock.com